|
|
 Previous Article | Table of Contents | Next Article 
Antisense Oligodeoxyribonucleotides Suppress Hematologic Cell Growth Through Stepwise Release of Deoxyribonucleotides
J.L. Vaerman,
P. Moureau,
F. Deldime,
P. Lewalle,
C. Lammineur,
F. Morschhauser, and
P. Martiat
From the Laboratoire de Biologie Moléculaire Hématologique, Cliniques St Luc, Université Catholique de Louvain, Clos Chapelle-aux-champs, Brussels, Belgium.
Antisense oligodeoxyribonucleotides (ODNs) are now being extensively investigated in an attempt to achieve cell growth suppression through specific targeting of genes related to cell proliferation, despite increasing evidence of non-antisense cytotoxic effects. In the context of anti-BCR/ABL antisense strategies in chronic myeloid leukemia, we have re-examined the antiproliferative effect of phosphodiester and phosphorothioate ODNs on the leukemic cell line BV173 and on CD34+ bone marrow cells in liquid culture. The 3' sequences of the ODNs determine their effect. At concentrations of 10 µmol/L (for phosphorothioate ODNs) or 25 µmol/L (for phosphodiester ODNs), all the tested ODNs exert an antiproliferative activity, except those that contain a cytosine residue at either their two most terminal 3' positions. We show that this antiproliferative effect is due to the toxicity of the d-NMPs (5' monophosphate deoxyribonucleosides), the enzymatic hydrolysis products of the ODNs in culture medium. The toxicity of the d-NMPs on hematologic cells depends on their nature (d-CMP [2'deoxycytidine 5'-monophosphate] is not cytotoxic), on their concentration (d-GMP [2'-deoxyguanosine 5'-monophosphate], TMP [thymidine 5'-monophosphate], and d-AMP [2'-deoxyadenosine 5'-monophosphate] are cytotoxic at concentrations between 5 and 10 µmol/L), and on the coincident presence of other d-NMPs in the culture medium (d-CMP neutralizes the toxicity of d-AMP, d-GMP, or TMP). The antiproliferative activity of ODNs is thus restricted to conditions where the 3' hydrolysis process by exonucleases generates significant amounts of d-NMPs with a low proportion of d-CMP. Our results reveal a novel example of a nonantisense effect of ODNs, which should be taken into account when performing any experiment using assumed antisense ODNs.
Blood, Vol. 90 No. 1 (July 1), 1997:
pp. 331-339
© 1997 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
V. Rapozzi, S. Cogoi, and L. E. Xodo
Antisense locked nucleic acids efficiently suppress BCR/ABL and induce cell growth decline and apoptosis in leukemic cells.
Mol. Cancer Ther.,
July 1, 2006;
5(7):
1683 - 1692.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. B. Opalinska, B. Machalinski, J. Ratajczak, M. Z. Ratajczak, and A. M. Gewirtz
Multigene Targeting with Antisense Oligodeoxynucleotides: An Exploratory Study Using Primary Human Leukemia Cells
Clin. Cancer Res.,
July 1, 2005;
11(13):
4948 - 4954.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Dias and C. A. Stein
Antisense Oligonucleotides: Basic Concepts and Mechanisms
Mol. Cancer Ther.,
March 1, 2002;
1(5):
347 - 355.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Cieslak, J. Niewiarowska, M. Nawrot, M. Koziolkiewicz, W. J. Stec, and C. S. Cierniewski
DNAzymes to beta 1 and beta 3 mRNA Down-regulate Expression of the Targeted Integrins and Inhibit Endothelial Cell Capillary Tube Formation in Fibrin and Matrigel
J. Biol. Chem.,
February 22, 2002;
277(9):
6779 - 6787.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Koziolkiewicz, E. Gendaszewska, M. Maszewska, C. A. Stein, and W. J. Stec
The mononucleotide-dependent, nonantisense mechanism of action of phosphodiester and phosphorothioate oligonucleotides depends upon the activity of an ecto-5'-nucleotidase
Blood,
August 15, 2001;
98(4):
995 - 1002.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. d. Diesbach, C. Berens, F. N'Kuli, M. Monsigny, E. Sonveaux, R. Wattiez, and P. J. Courtoy
Identification, purification and partial characterisation of an oligonucleotide receptor in membranes of HepG2 cells
Nucleic Acids Res.,
February 15, 2000;
28(4):
868 - 874.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Bergh, M. Ehinger, I. Olsson, S. E. W. Jacobsen, and U. Gullberg
Involvement of the Retinoblastoma Protein in Monocytic and Neutrophilic Lineage Commitment of Human Bone Marrow Progenitor Cells
Blood,
September 15, 1999;
94(6):
1971 - 1978.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Schmajuk, H. Sierakowska, and R. Kole
Antisense Oligonucleotides with Different Backbones. MODIFICATION OF SPLICING PATHWAYS AND EFFICACY OF UPTAKE
J. Biol. Chem.,
July 30, 1999;
274(31):
21783 - 21789.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. G. Wickremasinghe and A. V. Hoffbrand
Biochemical and Genetic Control of Apoptosis: Relevance to Normal Hematopoiesis and Hematological Malignancies
Blood,
June 1, 1999;
93(11):
3587 - 3600.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Chen, C. S. Song, Y. Lavrovsky, B. Bi*, B. Chatterjee, and A. K. Roy
Catalytic Cleavage of the Androgen Receptor Messenger RNA and Functional Inhibition of Androgen Receptor Activity by a Hammerhead Ribozyme
Mol. Endocrinol.,
October 1, 1998;
12(10):
1558 - 1566.
[Abstract]
[Full Text]
|
|
|
|
|
